home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Syndax Pharmaceuticals, Inc. - Common Stock (NQ:SNDX)

21.39 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Jan 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Syndax Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

12 Health Care Stocks Moving In Friday's After-Market Session ↗

September 29, 2023

Via Benzinga

Why SeaStar Medical Holding Shares Are Trading Higher By Around 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

September 29, 2023

Gainers Blue Apron Holdings, Inc. (NASDAQ: APRN) climbed 133.5% to $12.82 after the company announced an agreement to be acquired by Wonder Group for $13 per share.

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

September 29, 2023

Friday's session saw 112 companies set new 52-week lows.

Via Benzinga

Earnings Scheduled For August 3, 2023 ↗

August 03, 2023

Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million.

Via Benzinga

Vail Resorts, Carnival, Opera And Other Big Stocks Moving Lower On Friday ↗

September 29, 2023

U.S. stocks traded higher, with the Nasdaq Composite gaining around 1% on Friday. Here are some big stocks recording losses in today’s session. Corcept Therapeutics Incorporated (NASDAQ: CORT) shares...

Via Benzinga

Topics Stocks

Stocks That Hit 52-Week Lows On Thursday ↗

September 21, 2023

During the session on Thursday, 461 stocks hit new 52-week lows.

Via Benzinga

Citigroup Maintains Buy Rating for Syndax Pharmaceuticals: Here's What You Need To Know ↗

July 26, 2023

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

September 15, 2023

Friday's session saw 169 companies set new 52-week lows.

Via Benzinga

What 7 Analyst Ratings Have To Say About Syndax Pharmaceuticals ↗

July 25, 2023

Via Benzinga

Syndax-Incyte Partnered Chronic Graft-Versus-Host Disease Achieves Primary Endpoint In Pivotal Trial, FDA Submission Planned By 2023 End ↗

July 24, 2023

Syndax Pharmaceuticals (NASDAQ: SNDX) and Incyte Corporation (NASDAQ: INCY) announced topline data from the AGAVE-201 trial of axatilimab, in adult and pediatric patients with chronic graft-versus-host...

Via Benzinga

Syndax Pharmaceuticals Earnings Preview ↗

May 05, 2023

Via Benzinga

Expert Ratings for Syndax Pharmaceuticals ↗

March 01, 2023

Via Benzinga

Syndax Pharmaceuticals's Earnings: A Preview ↗

February 27, 2023

Via Benzinga

Analyst Expectations for Syndax Pharmaceuticals's Future ↗

January 31, 2023

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

September 11, 2023

Monday's session saw 175 companies set new 52-week lows.

Via Benzinga

Syndax Pharmaceuticals Set for Potential Breakthrough with Revumenib: Analyst Calls It 'Potentially Best-In-Class' In Competitive Landscape ↗

July 11, 2023

Guggenheim Partners initiated coverage on Syndax Pharmaceuticals Inc (NASDAQ: SNDX) with a BUY rating and a

Via Benzinga

Earnings Scheduled For May 8, 2023 ↗

May 08, 2023

Companies Reporting Before The Bell • HNI (NYSE:HNI) is likely to report quarterly loss at $0.03 per share on revenue of $462.26 million.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 27, 2023 ↗

July 27, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2023 ↗

January 31, 2023

Via Benzinga

Syndax Highlights Durable Remissions For Revumenib In Acute Leukemia Patients ↗

November 03, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 11, 2023 ↗

July 11, 2023

Via Benzinga

United Natural Foods, Ollie's Bargain, Smith & Wesson Brands And Some Other Big Stocks Moving Lower On Wednesday ↗

December 07, 2022

U.S. stocks traded mostly lower, with the Nasdaq Composite dropping over 60 points on Wednesday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Earnings Scheduled For February 28, 2023 ↗

February 28, 2023

Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report earnings for its fourth quarter.

Via Benzinga

Earnings Scheduled For November 3, 2022 ↗

November 03, 2022

Companies Reporting Before The Bell • Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion.

Via Benzinga

Earnings Preview For Syndax Pharmaceuticals ↗

November 02, 2022

Syndax Pharmaceuticals (NASDAQ:SNDX) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

Stock Market Rally Rises On Inflation Data; Nvidia, Micron, Tesla, Disney In Focus: Weekly Review ↗

August 12, 2022

The major indexes continued to advance, despite some key warnings.

Via Investor's Business Daily

Amphastar, Syndax Top Second-Quarter Estimates, But Runaway Biotechs At A Standstill ↗

August 08, 2022

Amphastar came in well above forecasts, while Syndax had fewer than expected losses.

Via Investor's Business Daily

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

July 07, 2022

Gainers

Via Benzinga

Earnings Scheduled For August 8, 2022 ↗

August 08, 2022

Companies Reporting Before The Bell • Pyxis Tankers (NASDAQ:PXS) is likely to report earnings for its second quarter.

Via Benzinga

Syndax Pharmaceuticals Stock Sees RS Rating Rise To 92 ↗

June 30, 2022

Syndax Pharmaceuticals stock saw a positive improvement to its Relative Strength (RS) Rating on Thursday, with an upgrade from 80 to 92.

Via Investor's Business Daily

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com